Welcome to our dedicated page for Definium Therapeutics SEC filings (Ticker: DFTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Definium Therapeutics, Inc. (DFTX) SEC filings page on Stock Titan is designed to help readers review the company’s regulatory disclosures in one place. While no specific filings are listed in the provided data, Definium references documents such as its Annual Report on Form 10-K and Quarterly Reports on Form 10-Q in its public communications, indicating that it files reports with the U.S. Securities and Exchange Commission.
Stock Titan connects to the SEC’s EDGAR system so that when Definium Therapeutics submits new filings, they can be displayed with AI-generated summaries. These summaries are intended to highlight key themes in lengthy documents, such as risk factor discussions, updates on the company’s psychiatric and neurological drug pipeline, and commentary on clinical study progress for candidates like DT120 ODT and DT402 as described in the company’s public statements.
For investors and researchers, this page can provide access to core filing types, including annual reports on Form 10-K and quarterly reports on Form 10-Q, once available. It can also surface other filing categories that may be relevant over time, such as registration statements or current reports, which often discuss material events, clinical milestones, or capital-raising activities referenced in the company’s forward-looking disclosures.
In addition to listing documents as they are filed, Stock Titan’s AI tools can help explain complex regulatory language in more accessible terms. This can be useful when reviewing sections that discuss Definium Therapeutics’ focus on psychedelic-inspired psychiatry, its clinical trial programs in generalized anxiety disorder, major depressive disorder, and autism spectrum disorder, and the risks and uncertainties the company highlights in its own cautionary statements.
Definium Therapeutics, Inc. Chief Medical Officer Daniel Karlin reported an open-market sale of 8,018 Common Shares on March 25, 2026 at a weighted average price of $18.47 per share. According to the footnotes, these shares were sold to satisfy withholding tax obligations tied to the settlement of vested restricted stock units under a Rule 10b5-1 sell-to-cover plan adopted on June 14, 2022.
After this transaction, Karlin directly owns 413,317 Common Shares, which includes 1,586 shares acquired through the Definium Therapeutics, Inc. 2024 Employee Share Purchase Plan. This filing reflects a tax-related, pre-planned disposition rather than a discretionary sale of a large ownership stake.
Definium Therapeutics, Inc. Chief Legal Officer Mark Sullivan sold 10,702 Common Shares on March 25, 2026 at a weighted average price of $18.47. According to the filing, the shares were sold to satisfy withholding tax obligations tied to vested restricted stock units under a Rule 10b5-1 sell-to-cover plan adopted on March 14, 2024. Following this tax-related sale, he directly holds 271,079 Common Shares, which includes 793 shares acquired under the company’s 2024 Employee Share Purchase Plan.
Definium Therapeutics, Inc. Chief Executive Officer Robert Barrow reported an open-market sale of 24,431 Common Shares at a weighted average price of $18.47 per share. The shares were sold to satisfy withholding tax obligations linked to vested restricted stock units under a Rule 10b5-1 sell-to-cover plan adopted on June 15, 2022.
Following this transaction, Barrow directly holds 752,454 Common Shares, and this amount includes 1,586 shares acquired under the Definium Therapeutics, Inc. 2024 Employee Share Purchase Plan. Because the sale was for tax withholding under a pre-planned trading arrangement, it reflects a routine administrative event rather than a discretionary change in ownership.
Robert Barrow filed a Form 144 reporting an intended sale of 24,431 shares of Common stock of DFTX on 03/25/2026, described as restricted stock vesting under a registered plan. The filing also shows a prior sale of 25,791 shares on 12/26/2025.
Daniel Karlin filed a Form 144 reporting 8,018 shares of Common Stock to be sold on 03/25/2026. The filing states the shares relate to restricted stock vesting under a registered plan and lists the disposition as Issuer with reason "Services Rendered". The form also shows 5,600 shares sold on 12/26/2025 with proceeds of $73,622.00.
Mark Sullivan reports intent to sell 10,702 shares of Common Stock on 03/25/2026. The filing lists the shares as restricted stock vesting under a registered plan and identifies the transaction as involving the issuer. The filing also discloses a prior sale of 11,276 shares on 12/26/2025.
Definium Therapeutics, Inc. is a late-stage clinical biopharmaceutical company focused on novel psychedelic-derived treatments for brain health disorders. Its lead candidate, DT120 ODT (lysergide D-tartrate), is in Phase 3 programs for generalized anxiety disorder (GAD) and major depressive disorder (MDD), following a Phase 2b GAD trial that met primary and key secondary endpoints and received FDA breakthrough therapy designation and a UK ILAP Innovation Passport.
The GAD Phase 3 program includes the Voyage and Panorama trials, while MDD trials include Emerge and Ascend, each with randomized, double-blind, placebo-controlled Part A phases and 40‑week open‑label extensions. A second candidate, DT402 (R(-)-MDMA), is in a Phase 2a trial for autism spectrum disorder. The company reports no approved products, ongoing net losses, the need for substantial additional capital, reliance on third-party manufacturers and CROs, and regulatory and reimbursement risks, particularly given its use of controlled substances.
Definium Therapeutics reported a larger full-year 2025 net loss of $183.8 million, compared with $108.7 million in 2024, as it ramped late-stage development for its psychedelic-based therapies.
Cash, cash equivalents and investments rose to $411.6 million as of December 31, 2025, up from $273.7 million a year earlier, helped by a $259 million equity financing completed in the fourth quarter. The company expects this cash to fund operations into 2028.
Research and development expenses increased to $117.7 million from $65.3 million, driven mainly by higher DT120 program spending and expanded R&D staffing. General and administrative costs rose to $48.6 million from $38.6 million, reflecting greater professional services, pre-commercial efforts, and personnel expenses.
Definium highlighted progress across four Phase 3 trials of DT120 ODT in major depressive disorder and generalized anxiety disorder, with its Emerge MDD study fully enrolled and multiple topline readouts anticipated in 2026. It also advanced DT402 into a Phase 2a study for autism spectrum disorder.
Definium Therapeutics, Inc. has a large shareholder group led by Commodore Capital LP reporting beneficial ownership of 7,428,775 common shares, representing 7.2% of the company as of December 31, 2025. This position includes 2,000,000 common shares plus 5,428,775 shares that can be acquired through a pre-funded warrant, which is subject to a 9.99% beneficial ownership limitation. The ownership percentage is based on 98,509,279 common shares reported outstanding as of October 31, 2025, plus the warrant shares. The filing is made jointly by Commodore Capital LP, Commodore Capital Master LP, and managing partners Robert Egen Atkinson and Michael Kramarz, who certify that the securities are not held for the purpose of changing or influencing control of the issuer. The issuer recently changed its name from Mind Medicine (MindMed) Inc. to Definium Therapeutics, Inc.
Driehaus Capital Management LLC, a Delaware investment adviser, reported beneficial ownership of Definium Therapeutics, Inc. common stock. Driehaus has shared voting and dispositive power over 6,537,202 shares, representing 6.64% of the company’s common stock as of the event date.
The shares are held in numerous fully discretionary client accounts managed by Driehaus, which reports potential voting and dispositive power, while clients generally do not hold more than 5% of the class individually. Driehaus states the holdings are maintained in the ordinary course of business and not for the purpose of changing or influencing control of Definium Therapeutics.